This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A High- and Low-Dose Double-blind Comparison With Placebo

Joyce G. Small, MD; Steven R. Hirsch, MPhil, MD, FRCP, FRCPPsych; Lisa A. Arvanitis, MD; Barbara G. Miller, MS; Christopher G. G. Link, MB, ChB, MPhil, MRCPsych, Dip Pharm Med, MFPM; Seroquel Study Group

Arch Gen Psychiatry. 1997;54(6):549-557.

Abstract
Background
Quetiapine fumarate (Seroquel [ICI 204,636]) is an atypical dibenzothiazepine antipsychotic with a greater affinity for 5-hydroxytryptamine₂ (5-HT₂) receptors than for D₂ dopamine receptors; its efficacy in patients with schizophrenia was shown in early phase 2 trials (maximum dose, 750 mg/d).

Methods
In this multicenter, double-blind, placebo-controlled trial, 286 patients hospitalized with chronic or subchronic schizophrenia (DSM-III-R) were randomized to 6 weeks of treatment with high-dose quetiapine fumarate (>750 mg/d), n=96; low-dose quetiapine fumarate (>250 mg/d), n=94; or placebo, n=96. The Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression Severity of Illness item scores were the primary efficacy variables. Secondary efficacy variables included the BPRS positive-symptom cluster score, the Modified Scale for the Assessment of Negative Symptoms summary score (United States only), and the total score from the negative scale of the Positive and Negative Syndrome Scale (Europe only). Scores were analyzed using an analysis of covariance for change from baseline at end point with last observations carried forward. The model included baseline score (covariate), center, and treatment. Extrapyramidal symptoms were assessed using the Simpson-Angus Scale and the Barnes Akathisia Scale; abnormal involuntary movements were assessed using the Abnormal Involuntary Movement Scale. Frequency distributions of grouped change-from-baseline scores were analyzed using ² tests.

Results
Of 280 patients in whom the efficacy of quetiapine was evaluated, 159 (42% of those receiving high-dose treatment; 57%, low-dose treatment; and 59%, placebo) withdrew before trial completion, primarily because of treatment failure. Significant (P<.001, BPRS; P=.003, Clinical Global Impression Severity of Illness item; and P=.003, BPRS positive-symptom cluster) differences were identified between patients receiving high-dose quetiapine and placebo for both primary efficacy variables, with end point differences in the BPRS positive-symptom cluster score showing quetiapine's consistency in reducing positive symptoms. The reduction of negative symptoms was less consistent; high-dose quetiapine was superior on the Modified Scale for the Assessment of Negative Symptoms but not on the negative scale of the Positive and Negative Syndrome Scale. Quetiapine was well tolerated and did not induce extrapyramidal symptoms, sustained elevations of prolactin, or clinically significant changes in hematologic parameters.

Conclusions
Quetiapine is an effective antipsychotic with a favorable safety profile. The optimum dose is probably greater than 250 mg/d.

Author Affiliations
From the Division of Mental Health, Larue D. Carter Memorial Hospital, Indianapolis, Ind (Dr Small); Departments of Psychiatry, Charing Cross Hospital, London, England (Dr Hirsch); Clinical and Medical Affairs, Zeneca Pharmaceuticals, Wilmington, Del (Dr Arvanitis and Ms Miller); and Medical Affairs, Zeneca Pharmaceuticals, Macclesfield, England (Dr Link). A complete list of the members of the Seroquel Study Group appears in the box on page 552.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The potential relationship between QTc interval prolongation and ziprasidone treatment: three cases
Eker et al.
J Psychopharmacol 2009;23:993-996.
ABSTRACT  

Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features
Rabinowitz et al.
Schizophr Bull 2009;35:775-788.
ABSTRACT | FULL TEXT  

Randomized, Double-Blind, Placebo-Controlled Study of Paliperidone Extended-Release and Quetiapine in Inpatients With Recently Exacerbated Schizophrenia
Canuso et al.
Am. J. Psychiatry 2009;166:691-701.
ABSTRACT | FULL TEXT  

Prolactin and dopamine: What is the connection? A Review Article
Fitzgerald and Dinan
J Psychopharmacol 2008;22:12-19.
ABSTRACT  

ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders
Noel
Am J Health Syst Pharm 2007;64:863-876.
FULL TEXT  

Subjecting Meta-analyses to Closer Scrutiny: Little Support for Differential Efficacy Among Second-Generation Antipsychotics at Equivalent Doses.
Tandon and Nasrallah
Arch Gen Psychiatry 2006;63:935-937.
FULL TEXT  

Subjecting Meta-analyses to Closer Scrutiny: Little Support for Differential Efficacy Among Second-Generation Antipsychotics at Equivalent Doses--Reply
Davis et al.
Arch Gen Psychiatry 2006;63:937-939.
FULL TEXT  

Increased libido associated with quetiapine
Menon et al.
J Psychopharmacol 2006;20:125-127.
ABSTRACT  

Dropout Rates in Placebo-Controlled and Active-Control Clinical Trials of Antipsychotic Drugs: A Meta-analysis
Kemmler et al.
Arch Gen Psychiatry 2005;62:1305-1312.
ABSTRACT | FULL TEXT  

The efficacy and safety of quetiapine for treatment of geriatric psychosis
Yang et al.
J Psychopharmacol 2005;19:661-666.
ABSTRACT  

Clinical implications of Brief Psychiatric Rating Scale scores
LEUCHT et al.
Br. J. Psychiatry 2005;187:366-371.
ABSTRACT | FULL TEXT  

Control Group Bias in Randomized Atypical Antipsychotic Medication Trials for Schizophrenia
Woods et al.
Arch Gen Psychiatry 2005;62:961-970.
ABSTRACT | FULL TEXT  

Acute Akathisia Associated With Quetiapine Use
Catalano et al.
Psychosomatics 2005;46:291-301.
ABSTRACT | FULL TEXT  

Pharmacotherapy and Health Care Costs Among Patients With Schizophrenia and Newly Diagnosed Diabetes
Leslie and Rosenheck
Psychiatr. Serv. 2005;56:803-809.
ABSTRACT | FULL TEXT  

Conventional and Atypical Antipsychotics and the Risk of Hospitalization for Ventricular Arrhythmias or Cardiac Arrest
Liperoti et al.
Arch Intern Med 2005;165:696-701.
ABSTRACT | FULL TEXT  

Schizophrenia and Other Psychotic Disorders
Jibson et al.
Focus 2004;2:17-30.
ABSTRACT | FULL TEXT  

The Barnes Akathisia Rating Scale-Revisited
Barnes
J Psychopharmacol 2003;17:365-370.
ABSTRACT  

Schizophrenia
Freedman
NEJM 2003;349:1738-1749.
FULL TEXT  

Seizures Associated with Quetiapine Treatment
Dogu et al.
The Annals of Pharmacotherapy 2003;37:1224-1227.
ABSTRACT | FULL TEXT  

Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective Disorder
Potkin et al.
Arch Gen Psychiatry 2003;60:681-690.
ABSTRACT | FULL TEXT  

A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis et al.
Arch Gen Psychiatry 2003;60:553-564.
ABSTRACT | FULL TEXT  

Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences: Selective literature review
WIECK and HADDAD
Br. J. Psychiatry 2003;182:199-204.
ABSTRACT | FULL TEXT  

Status of Patients With First-Episode Psychosis After One Year of Phase-Specific Community-Oriented Treatment
Malla et al.
Psychiatr. Serv. 2002;53:458-463.
ABSTRACT | FULL TEXT  

Association of Diabetes Mellitus With Use of Atypical Neuroleptics in the Treatment of Schizophrenia
Sernyak et al.
Am. J. Psychiatry 2002;159:561-566.
ABSTRACT | FULL TEXT  

Antipsychotic Medication Adherence: Is There a Difference Between Typical and Atypical Agents?
Dolder et al.
Am. J. Psychiatry 2002;159:103-108.
ABSTRACT | FULL TEXT  

Quetiapine-Induced Extrapyramidal Side Effects in Patients with Parkinson's Disease: Case Report
Sommer
J Geriatr Psychiatry Neurol 2001;14:99-100.
ABSTRACT  

A Positron Emission Tomography Study of Quetiapine in Schizophrenia: A Preliminary Finding of an Antipsychotic Effect With Only Transiently High Dopamine D2 Receptor Occupancy
Kapur et al.
Arch Gen Psychiatry 2000;57:553-559.
ABSTRACT | FULL TEXT  

Review: most antipsychotic drugs are associated with weight gain
Fenton
Evid. Based Ment. Health 2000;3:58-58.
FULL TEXT  

Clinical Experience with Quetiapine in Elderly Patients with Psychotic Disorders
Madhusoodanan et al.
J Geriatr Psychiatry Neurol 2000;13:28-32.
ABSTRACT  

Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis
Allison et al.
Am. J. Psychiatry 1999;156:1686-1696.
ABSTRACT | FULL TEXT  

Older Patients With Schizophrenia: Challenges in the Coming Decades
Palmer et al.
Psychiatr. Serv. 1999;50:1178-1183.
ABSTRACT | FULL TEXT  

Psychopharmacology: Novel Antipsychotic Medications in the Treatment of Children and Adolescents
Malone et al.
Psychiatr. Serv. 1999;50:171-174.
FULL TEXT  

Psychopharmacological Treatment of Schizophrenia: What Social Workers Need to Know
Bentley
Research on Social Work Practice 1998;8:384-405.
ABSTRACT